← Back to headlines
argenx SE Announces Positive Phase 3 Myositis Trial Results
argenx SE (ARGX) has successfully completed its Phase 3 Myositis trial, with discussions ongoing regarding the significance of subgroup results.
22 Aug, 00:53 — 22 Aug, 00:53
Sources
Showing 1 of 1 sources
